Europe gives green light to two new therapeutic options against coronavirus

The European Medicines Agency (EMA) yesterday issued a favorable opinion on two treatments against covid-19 –Ronapreve and Regkiron– that the European Commission considered promising therapeutic options in accordance with the European Union (EU) Strategy on Therapeutic Options against Covid-19.

These medications should be used during the early stages of the infection and are based on antiviral monoclonal antibodies —Proteins designed to bind to a specific target, in this case, the peak protein or S SARS-CoV-2, which the virus uses to enter human cells.

These medications should be used during the early stages of the infection.

Stella Kyriakides, the agency’s Commissioner for Health and Food Safety, expressed his satisfaction at this important advance in a press release: Covid-19 that we’re experimenting with, it’s comforting that there are so many promising therapies in development. Today we are taking an important step towards our goal of authorizing up to five new treatments in the EU by the end of the year.”

New therapeutic options

The Committee on Medicines for Human Use (CHMP) of the EMA evaluated data from studies showing that treatment with Ronapreve or Regkirona significantly reduces the hospitalization and the deaths in patients at risk of serious covid-19. Other research has also shown that Ronapreve reduces the likelihood of suffering from this disease if a family member becomes infected with SARS-CoV-2.

“Although the EU has one of the highest vaccination rates in the world, many people will continue to fall ill and will need safe and effective therapies to fight the infection and improve their prospects not only for a faster recovery, but also for survival,” he explains. the commissioner.

Specifically, it was recommended to use Ronapreve for the prevention and treatment of covid-19 in adults and adolescents (from 12 years and weighing at least 40 kg) who do not need oxygen and are at greater risk of worsening the disease.

as to Regkiron, experts have suggested its approval for treatment in adults infected with SARS-CoV-2 who, like Ronapreve, do not need supplemental oxygen and are at high risk for severe COVID-19.

Medicines and vaccinations, keys against covid-19

The EMA is evaluating six other drugs that may soon receive authorization, provided the final data demonstrate their quality, safety and efficacy.

“The progression of the pandemic across the EU shows that the situation remains delicate and that it is extremely important that patients have access to safe and effective treatment. But what is really clear is that we must continue with the vaccination campaign, especially in the member states with the lowest rates”, he stresses Kyriakides. “Vaccination is the only preventive solution to get out of the crisis.”


Related News

Leave A Reply

Please enter your comment!
Please enter your name here